Acrivon Therapeutics, Inc. Common Stock
ACRV
Cena:
$ 1.75
-0.04 (-2.23%)
Valuace
70
Růst
0
Zdraví
75
Zprávy
Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
ACRIVON THERAPEUTICS ANNOUNCES LATE-BREAKING ORAL PRESENTATION AT UPCOMING EUROPEAN SOCIETY OF GYNECOLOGICAL ONCOLOGY (ESGO) ANNUAL INTERNATIONAL CONGRESS
23-01-2026
GLOBALLY RECOGNIZED KEY OPINION LEADER PANAGIOTIS (PANOS) KONSTANTINOPOULOS, M.D., PH.D., DANA-FARBE...
Více zde
ACRIVON THERAPEUTICS ANNOUNCES POSITIVE ACR-368 PHASE 2B ENDOMETRIAL CANCER CLINICAL DATA WITH EU EXPANSION TO ACCELERATE ENROLLMENT, INITIAL ACR-2316 CLINICAL DATA, AND ACR-6840, ITS NEXT AP3-ENABLED DEVELOPMENT CANDIDATE, TARGETING CDK11
08-01-2026
ELECTRONIC DATA CAPTURE (EDC) EXTRACT FROM THE ONGOING ACR-368 REGISTRATIONAL-INTENT PHASE 2B MONOTH...
Více zde
ACRIVON THERAPEUTICS TO ANNOUNCE CLINICAL UPDATE ON ITS ONGOING PHASE 2B STUDIES AND PLANNED CONFIRMATORY PHASE 3 TRIAL FOR ACR-368, INITIAL CLINICAL DATA ON ACR-2316, AND OTHER AP3 PIPELINE UPDATES VIA WEBCAST
06-01-2026
COMPANY TO HOST CONFERENCE CALL AND WEBCAST AT 8:30 A.M. ET ON THURSDAY, JANUARY 8, 2026 COMPANY TO ...
Více zde
UPDATE -- ACRIVON THERAPEUTICS TO ANNOUNCE CLINICAL UPDATE ON ITS ONGOING PHASE 2B STUDIES AND PLANNED CONFIRMATORY PHASE 3 TRIAL FOR ACR-368, INITIAL CLINICAL DATA ON ACR-2316, AND OTHER AP3 PIPELINE UPDATES VIA WEBCAST
17-12-2025
WATERTOWN, MASS., DEC. 17, 2025 (GLOBE NEWSWIRE) -- ACRIVON THERAPEUTICS, INC. (“ACRIVON” OR “...
Více zde
ACRIVON THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS
13-11-2025
ADVANCEMENT OF ACR-368 IN REGISTRATIONAL-INTENT PHASE 2B TRIAL FOR THE TREATMENT OF PATIENTS WITH EN...
Více zde
ACRIVON THERAPEUTICS HIGHLIGHTS ITS POWERFUL GENERATIVE PHOSPHOPROTEOMICS AP3 PLATFORM WITH COMPELLING PRECLINICAL DATA FOR ACR-2316 WITH THREE PRESENTATIONS AT THE UPCOMING AACR-NCI-EORTC INTERNATIONAL CONFERENCE
22-10-2025
AP3 GENERATIVE AI KAISR MODEL GLOBALLY ASSESSES DRUG EFFECTS ON THE ENTIRE INTRACELLULAR PROTEIN SIG...
Více zde
ACRIVON THERAPEUTICS ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
01-10-2025
WATERTOWN, MASS., OCT. 01, 2025 (GLOBE NEWSWIRE) -- ACRIVON THERAPEUTICS, INC. (“ACRIVON” OR “...
Více zde
ACRIVON THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS
13-08-2025
CONTINUED ADVANCEMENT OF TWO CLINICAL-STAGE ASSETS, BOTH WITH CLINICALLY DEMONSTRATED SINGLE-AGENT A...
Více zde
ACRIVON THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS
14-05-2025
CORPORATE R&D EVENT HIGHLIGHTED POSITIVE ACR-368 DATA IN ENDOMETRIAL CANCER PATIENTS WHO HAD ALL REC...
Více zde
ACRIVON THERAPEUTICS TO REVEAL THE MOLECULAR MECHANISMS DRIVING STRONG SINGLE-AGENT ACTIVITY OF ACR-2316, ITS AP3-ENABLED CLINICAL STAGE WEE1/PKMYT1 INHIBITOR, AT THE AACR ANNUAL MEETING 2025
25-04-2025
PRESENTATION TO HIGHLIGHT HOW AP3 GENERATIVE PHOSPHOPROTEOMIC ANALYSES UNCOVER HOW ACR-2316 INDUCES ...
Více zde
ACRIVON THERAPEUTICS APPOINTS WORLD-RENOWNED ONCOLOGY KEY OPINION LEADER AND CLINICAL INVESTIGATOR MANSOOR RAZA MIRZA, M.D., AS CHIEF MEDICAL OFFICER
07-04-2025
DISTINGUISHED, HIGHLY ACCOMPLISHED CLINICIAN WITH STELLAR TRACK RECORD OF SUCCESSFULLY LEADING NUMER...
Více zde
ACRIVON THERAPEUTICS PROVIDES PROGRAM UPDATES AND FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS
27-03-2025
GENERATIVE PHOSPHOPROTEOMICS AP3 PLATFORM DESIGNED TO ENABLE STREAMLINED, RATIONAL DRUG DISCOVERY, W...
Více zde
ACRIVON THERAPEUTICS TO HOST CORPORATE R&D EVENT TO PROVIDE AP3 PLATFORM CAPABILITIES AND CLINICAL ACR-368 AND ACR-2316 PROGRAM UPDATES
19-03-2025
EVENT TO BE HELD VIA WEBCAST ON MARCH 25, 2025 AT 4:00 P.M. ET TO HIGHLIGHT DIFFERENTIATED DRUG DISC...
Více zde
ACRIVON THERAPEUTICS ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
16-10-2024
WATERTOWN, MASS., OCT. 16, 2024 (GLOBE NEWSWIRE) -- ACRIVON THERAPEUTICS, INC. (“ACRIVON” OR “...
Více zde
ACRIVON THERAPEUTICS ANNOUNCES INITIAL PATIENT DOSING IN PHASE 1 TRIAL OF ACR-2316, A NOVEL WEE1/PKMYT1 INHIBITOR DESIGNED USING AP3 FOR SUPERIOR SINGLE-AGENT ACTIVITY
11-10-2024
- FIRST PATIENT DOSED TWO QUARTERS AHEAD OF ORIGINAL TIMELINES IN ACRIVON PHASE 1 STUDY TO ASSESS SA...
Více zde
ACRIVON THERAPEUTICS REPORTS POSITIVE ENDOMETRIAL CANCER DATA FROM ONGOING ACR-368 REGISTRATIONAL INTENT PHASE 2 STUDY AT ESMO, ADVANCEMENT OF ACR-2316 INTO CLINIC AHEAD OF TIMELINES, AND PROGRESS ON ITS AP3 INTERACTOME FOR PROPRIETARY DATA ANALYSIS
14-09-2024
WATERTOWN, MASS., SEPT. 14, 2024 (GLOBE NEWSWIRE) -- ACRIVON THERAPEUTICS, INC. (“ACRIVON” OR ...
Více zde
ACRIVON THERAPEUTICS TO PRESENT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE
29-05-2024
WATERTOWN, MASS., MAY 29, 2024 (GLOBE NEWSWIRE) -- ACRIVON THERAPEUTICS, INC. (“ACRIVON” OR ...
Více zde
ACRIVON THERAPEUTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS
14-05-2024
WATERTOWN, MASS., MAY 14, 2024 (GLOBE NEWSWIRE) -- ACRIVON THERAPEUTICS, INC. (“ACRIVON” OR “A...
Více zde
ACRIVON THERAPEUTICS REPORTS INITIAL POSITIVE CLINICAL DATA FOR ACR-368 AND PIPELINE PROGRAM PROGRESS TODAY AT CORPORATE R&D EVENT
24-04-2024
• INITIAL ACR-368 PHASE 2B CLINICAL DATA IN PATIENTS WITH OVARIAN OR ENDOMETRIAL CANCERS (N=26; ...
Více zde
ACRIVON THERAPEUTICS TO HOST CORPORATE R&D EVENT HIGHLIGHTING AP3 AND PIPELINE PROGRESS, INCLUDING ONGOING PROSPECTIVE VALIDATION OF ACR-368 ONCOSIGNATURE WITH INITIAL PHASE 2 DATA FOR ACR-368, AND PRECLINICAL PROGRESS FOR ACR-2316
16-04-2024
WATERTOWN, MASS., APRIL 16, 2024 (GLOBE NEWSWIRE) -- ACRIVON THERAPEUTICS, INC. (“ACRIVON” OR ...
Více zde
ACRIVON THERAPEUTICS PRESENTS DATA AT AACR ANNUAL MEETING HIGHLIGHTING THE CAPABILITIES OF ACRIVON PREDICTIVE PRECISION PROTEOMICS (AP3) FOR THE DISCOVERY OF ACR-2316, A NOVEL, SELECTIVE WEE1/PKMYT1 INHIBITOR, AND THE IDENTIFICATION OF ACTIONABLE RESISTAN
10-04-2024
ACR-2316, WHICH WAS INTERNALLY DISCOVERED USING BIOLOGICAL SAR ENABLED BY AP3 TO OVERCOME LIMITATION...
Více zde
ACRIVON THERAPEUTICS ANNOUNCES $130 MILLION PRIVATE PLACEMENT FINANCING
09-04-2024
WATERTOWN, MASS, APRIL 09, 2024 (GLOBE NEWSWIRE) -- ACRIVON THERAPEUTICS, INC. (“ACRIVON” OR “...
Více zde
ACRIVON THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS
28-03-2024
WATERTOWN, MASS., MARCH 28, 2024 (GLOBE NEWSWIRE) -- ACRIVON THERAPEUTICS, INC. (“ACRIVON” OR ...
Více zde
ACRIVON THERAPEUTICS TO PRESENT DATA AT AACR ANNUAL MEETING DEMONSTRATING POWER OF ACRIVON PREDICTIVE PRECISION PROTEOMICS (AP3) PLATFORM AND ITS INTERNALLY-DISCOVERED, POTENT WEE1/PKMYT1 DEVELOPMENT CANDIDATE, ACR-2316
05-03-2024
ACR-2316, A NOVEL, SELECTIVE DUAL WEE1 AND PKMYT1 INHIBITOR DEVELOPMENT CANDIDATE, DESIGNED USING AP...
Více zde
ACRIVON THERAPEUTICS TO PARTICIPATE IN A PANEL DISCUSSION AT THE TD COWEN 44TH ANNUAL HEALTH CARE CONFERENCE
27-02-2024
WATERTOWN, MASS., FEB. 27, 2024 (GLOBE NEWSWIRE) -- ACRIVON THERAPEUTICS, INC. (“ACRIVON” OR “...
Více zde
ACRIVON THERAPEUTICS TO PRESENT AT THE OPPENHEIMER 34TH ANNUAL HEALTHCARE LIFE SCIENCES CONFERENCE
06-02-2024
WATERTOWN, MASS., FEB. 06, 2024 (GLOBE NEWSWIRE) -- ACRIVON THERAPEUTICS, INC. (“ACRIVON” OR “...
Více zde
ACRIVON THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
12-01-2024
WATERTOWN, MASS., JAN. 12, 2024 (GLOBE NEWSWIRE) -- ACRIVON THERAPEUTICS, INC. (“ACRIVON” OR “...
Více zde
ACRIVON THERAPEUTICS TO PRESENT AT THE PIPER SANDLER ANNUAL HEALTHCARE CONFERENCE
21-11-2023
WATERTOWN, MASS., NOV. 21, 2023 (GLOBE NEWSWIRE) -- ACRIVON THERAPEUTICS, INC. (“ACRIVON” OR “...
Více zde
ACRIVON THERAPEUTICS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS
09-11-2023
WATERTOWN, MASS., NOV. 09, 2023 (GLOBE NEWSWIRE) -- ACRIVON THERAPEUTICS, INC. (“ACRIVON” OR “...
Více zde
ACRIVON THERAPEUTICS PRESENTS DATA DEMONSTRATING CAPABILITIES OF ITS AP3 PLATFORM AND ACR-368 ONCOSIGNATURE ASSAY FOR PATIENT RESPONDER IDENTIFICATION AT THE AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS
16-10-2023
DATA PRESENTED ON THE APPLICATION OF ACRIVON PREDICTIVE PRECISION PROTEOMICS (AP3) FOR THE SUCCESSFU...
Více zde
| Datum | Typ | Otevřít EDGAR | Stáhnout dokument |
|---|---|---|---|
| 2026-01-08 00:00:00 | 8-K |  | Stáhnout |
| 2025-11-13 00:00:00 | 8-K | | Stáhnout |
| 2025-11-13 00:00:00 | 10-Q | | Stáhnout |
| 2025-09-05 01:00:00 | 8-K | | Stáhnout |
| 2025-09-05 00:00:00 | 8-K | | Stáhnout |
| 2025-08-13 01:00:00 | 8-K | | Stáhnout |
| 2025-08-13 01:00:00 | 10-Q | | Stáhnout |
| 2025-08-13 00:00:00 | 8-K | | Stáhnout |
| 2025-08-13 00:00:00 | 10-Q | | Stáhnout |
| 2025-06-13 01:00:00 | 8-K | | Stáhnout |
| 2025-06-13 00:00:00 | 8-K | | Stáhnout |
| 2025-05-14 01:00:00 | 8-K | | Stáhnout |
| 2025-05-14 01:00:00 | 10-Q | | Stáhnout |
| 2025-05-14 00:00:00 | 8-K | | Stáhnout |
| 2025-05-14 00:00:00 | 10-Q | | Stáhnout |
| 2025-04-07 01:00:00 | 8-K | | Stáhnout |
| 2025-04-07 00:00:00 | 8-K | | Stáhnout |
| 2025-03-27 00:00:00 | 8-K | | Stáhnout |
| 2025-03-27 00:00:00 | 10-K | | Stáhnout |
| 2025-03-26 23:00:00 | 8-K | | Stáhnout |
| 2025-03-26 23:00:00 | 10-K | | Stáhnout |
| 2025-03-25 00:00:00 | 8-K | | Stáhnout |
| 2025-03-24 23:00:00 | 8-K | | Stáhnout |
| 2025-03-14 00:00:00 | 8-K | | Stáhnout |
| 2025-03-13 23:00:00 | 8-K | | Stáhnout |
| 2024-11-13 00:00:00 | 8-K | | Stáhnout |
| 2024-11-13 00:00:00 | 10-Q | | Stáhnout |
| 2024-11-12 23:00:00 | 8-K | | Stáhnout |
| 2024-11-12 23:00:00 | 10-Q | | Stáhnout |
| 2024-10-11 01:00:00 | 8-K | | Stáhnout |
| 2024-10-11 00:00:00 | 8-K | | Stáhnout |
| 2024-09-16 01:00:00 | 8-K | | Stáhnout |
| 2024-09-16 00:00:00 | 8-K | | Stáhnout |
| 2024-08-13 01:00:00 | 8-K | | Stáhnout |
| 2024-08-13 01:00:00 | 10-Q | | Stáhnout |
| 2024-08-13 00:00:00 | 8-K | | Stáhnout |
| 2024-08-13 00:00:00 | 10-Q | | Stáhnout |
| 2024-06-21 01:00:00 | 8-K | | Stáhnout |
| 2024-06-21 00:00:00 | 8-K | | Stáhnout |
| 2024-05-14 01:00:00 | 8-K | | Stáhnout |
| 2024-05-14 01:00:00 | 10-Q | | Stáhnout |
| 2024-05-14 00:00:00 | 8-K | | Stáhnout |
| 2024-05-14 00:00:00 | 10-Q | | Stáhnout |
| 2024-04-24 01:00:00 | 8-K | | Stáhnout |
| 2024-04-24 00:00:00 | 8-K | | Stáhnout |
| 2024-04-09 01:00:00 | 8-K | | Stáhnout |
| 2024-04-09 00:00:00 | 8-K | | Stáhnout |
| 2024-03-28 00:00:00 | 8-K | | Stáhnout |
| 2024-03-28 00:00:00 | 10-K | | Stáhnout |
| 2024-03-27 23:00:00 | 8-K | | Stáhnout |
| 2024-03-27 23:00:00 | 10-K | | Stáhnout |
| 2024-03-04 00:00:00 | 8-K | | Stáhnout |
| 2024-03-03 23:00:00 | 8-K | | Stáhnout |
| 2024-02-08 00:00:00 | 8-K | | Stáhnout |
| 2024-02-07 23:00:00 | 8-K | | Stáhnout |
| 2024-01-08 00:00:00 | 8-K | | Stáhnout |
| 2024-01-07 23:00:00 | 8-K | | Stáhnout |
| 2023-12-08 00:00:00 | 8-K | | Stáhnout |
| 2023-12-07 23:00:00 | 8-K | | Stáhnout |
| 2023-11-09 00:00:00 | 8-K | | Stáhnout |
| 2023-11-09 00:00:00 | 10-Q | | Stáhnout |
| 2023-11-08 23:00:00 | 8-K | | Stáhnout |
| 2023-11-08 23:00:00 | 10-Q | | Stáhnout |
| 2023-09-05 01:00:00 | 8-K | | Stáhnout |
| 2023-09-05 00:00:00 | 8-K | | Stáhnout |
| 2023-08-11 01:00:00 | 8-K | | Stáhnout |
| 2023-08-11 01:00:00 | 10-Q | | Stáhnout |
| 2023-08-11 00:00:00 | 8-K | | Stáhnout |
| 2023-08-11 00:00:00 | 10-Q | | Stáhnout |
| 2023-06-22 01:00:00 | 8-K | | Stáhnout |
| 2023-06-22 00:00:00 | 8-K | | Stáhnout |
| 2023-06-05 01:00:00 | 8-K | | Stáhnout |
| 2023-06-05 00:00:00 | 8-K | | Stáhnout |
| 2023-05-09 01:00:00 | 8-K | | Stáhnout |
| 2023-05-09 01:00:00 | 10-Q | | Stáhnout |
| 2023-05-09 00:00:00 | 8-K | | Stáhnout |
| 2023-05-09 00:00:00 | 10-Q | | Stáhnout |
| 2023-05-01 01:00:00 | 8-K | | Stáhnout |
| 2023-05-01 00:00:00 | 8-K | | Stáhnout |
| 2023-04-25 01:00:00 | 8-K | | Stáhnout |
| 2023-04-25 00:00:00 | 8-K | | Stáhnout |
| 2023-03-28 01:00:00 | 8-K | | Stáhnout |
| 2023-03-28 01:00:00 | 10-K | | Stáhnout |
| 2023-03-28 00:00:00 | 8-K | | Stáhnout |
| 2023-03-28 00:00:00 | 10-K | | Stáhnout |
| 2023-03-13 00:00:00 | 8-K | | Stáhnout |
| 2023-03-12 23:00:00 | 8-K | | Stáhnout |
| 2023-03-03 00:00:00 | 8-K | | Stáhnout |
| 2023-03-02 23:00:00 | 8-K | | Stáhnout |
